Rejuvenation Technologies utilizes nucleoside-modified TERT mRNA to temporarily activate telomerase, enabling the safe extension of telomeres in human cells. This approach addresses the critical shortening of telomeres, which contributes to cellular aging and various age-related diseases, by potentially reversing the effects of aging at the chromosomal level.
Funding
$15.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AV+2Founders
Product
Problem
As cells divide, telomeres, the protective DNA sequences at the ends of chromosomes, shorten. Critically short telomeres can lead to cellular aging and various age-related diseases by impairing stem cell function and tissue regeneration.
Solution
Rejuvenation Technologies is developing a therapy that utilizes nucleoside-modified mRNA to temporarily activate telomerase, the enzyme responsible for telomere elongation. This approach aims to safely extend telomeres in specific cells, potentially reversing cellular aging and preventing or treating diseases associated with short telomeres. The company's technology employs targeted delivery via lipid nanoparticles to ensure the treatment reaches the intended cells while minimizing off-target effects. By temporarily activating telomerase, Rejuvenation Technologies seeks to avoid the cancer risks associated with permanent telomerase activation, offering a controlled and precise method for telomere extension.
Target Audience
The primary target audience includes patients with pulmonary fibrosis, liver disease, bone marrow failure, and other age-related diseases linked to telomere shortening, as well as clinical trial participants.
Features
- Nucleoside-modified TERT mRNA for temporary telomerase activation
- Proprietary lipid nanoparticle technology for targeted delivery to specific cells
- Controlled telomere extension to maintain safety and efficacy
- Advanced telomere length analysis and biomarker tracking for optimal treatment outcomes
- Focus on pulmonary fibrosis, liver disease, and bone marrow failure indications